Radiation Protection Dosimetry Advance Access published online on May 14, 2008
Radiation Protection Dosimetry, doi:10.1093/rpd/ncn081
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EVALUATION OF THE POPULATION DOSE TO THE UK POPULATION FROM THE NATIONAL HEALTH SERVICE BREAST SCREENING PROGRAMME
1 Quality Assurance Reference Centre, 9 Kingfisher Way, Silverlink Business Park, Wallsend NE28 9ND, UK
2 Warwickshire, Solihull and Coventry Breast Screening Service, Coventry and Warwickshire Hospital, Stoney Station Road, Coventry, CV1 4FH, UK
* Corresponding author: keith.faulkner{at}nhs.net
In the United Kingdom National Health Service Breast Screening Programme (NHSBSP), women aged between 50 and 70 y are invited for mammography every 3 y. Screening histories for each woman, over four screening rounds, were analysed. Data from five screening programmes were used to select 57 425 women into the study. Cases were selected on the basis of being between the ages of 50 and 53 at the start of the NHSBSP (i.e. between 1989 and 1992). Assessment of the outcome for each screening round for each woman involved assigning a simple outcome code. Each of the possible pathways through the four screening rounds was analysed. This comprises of 500 possible pathways. This data enabled the following information to be determined: (i) The number of times a woman attended the screening programme. (ii) The number of women referred for assessment at each screening round. This information may be used to deduce the population dose to this group of women averaged over four screening rounds. Patient doses have been monitored since the programme's inception and are typically 4.5 mGy for two-view screening. It is possible to determine the mean glandular dose received by this cohort of women over four screening rounds by multiplying the number of examinations by the mean glandular dose for a typical woman. Allowance has to be made for the number of projections taken at each screening round. Once a woman has been screened, she may be invited back for further assessment if an abnormality is found on her mammogram. A stereotactic attachment is used to determine where to place the biopsy device. Although the dose received during a normal screening mammogram is well known, the dose for a stereotactic procedure and other assessment procedures is less well known, partly because only a small part of the breast is directly irradiated during stereotaxis. However, the woman may have multiple exposures during this stage. A prospective survey of doses was completed to deduce the mean glandular dose at the first assessment stage and during stereotaxis. Numbers of films, including magnification films taken at first-stage assessment were established in the North East of England and Scotland by means of a postal survey. Average total mean glandular dose was deduced using previous survey data for the screening programme and a multiplying factor to allow for magnification film dose. On average 1.6 full field and 0.15 collimated contact films are taken for each woman (with 2.25 and 0.75 mGy film–1), 1.0 full field and 0.9 collimated magnification views. The mean magnification film dose to the assessed breast was 5.0 and 1.7 mGy for a collimated magnification film. A survey of 134 women at screening centres in the North East of England was performed to deduce the mean glandular dose from digital stereotaxis which is almost universally used in breast screening. A typical woman received a dose to the assessed breast of 4.5 mGy with a range of 1.3–17 mGy. This data may be used to deduce the total mean glandular dose over four screening rounds including the assessment stages. The estimated mean glandular dose to a typical woman invited to the screening programme is 
16 mGy, when allowance for attendance rate and assessment rate over each screening round is made. The mean glandular dose to the population is 4700 Sv y–1.
3 Present address: Cambridge Breast Unit, Box 97, Addenbrooke's Hospital, Cambridge CB22 2QQ, UK